Radient Pharmaceuticals (RPC) Tops Q4 EPS by 26c

Radient Pharmaceuticals (NYSE: RPC) reported Q4 EPS of $0.26. Revenue for the quarter came in at $81 million.

For earnings history and earnings-related data on Radient Pharmaceuticals (RPC) click here.

You May Also Be Interested In

• Ridgepost Capital Completes Acquisition of Stellus Capital Management, a Leading U.S. Direct Lender Specializing in the Lower-Middle Market
• ZenaTech raises Plurilock Security stake to 12% with new share purchase
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings